Category: Technology

Recombinant T cell clonotypes are provided that express T cell receptor alpha and T cell receptor beta polypeptides with specificity for human papillomavirus (HPV) type 16 E6 protein and that amplify in response to a therapeutic vaccine and traffic to ovarian lesional tissue in a patient whose HPV lesions regressed in response to the vaccine. Recombinant T cells expressing appropriate TCR alpha and beta complimentarity determining sequences for HPV 16 E6 binding and treating HPV-cased cancers are provided. Bifunctional proteins having TCR alpha and beta segments that bind to HPV 16 E6 residues 91-115 and a single chain Fv anti-CD3 antibody domain are provided. These bifunctional proteins can direct T cells to HPV-infected cells.

The present disclosure provides compositions and methods for selectively killing senescent cells, wherein the selective killing of senescent cells delays aging and treats age-related disorders.

The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.

Mutant Myxoma viruses are provided herein and methods of using these viruses to treat cancer or elicit an interferon response in a subject are also provided. The mutant Myxoma virus is modified to reduce or eliminate the activity or expression of Myxoma virus protein M62 as compared to a control virus. The mutant virus is capable of stimulating an interferon response in subjects after administration and can also lead to inhibition, reduction or elimination of the CD14+ tumor associated macrophage inhibition of CD4+ T cells in a subject having cancer and lead to a change in the tumor microenvironment to treat the cancer or work in combination with other cancer therapeutics to treat the cancer as described herein.

The present disclosure provides compositions and methods for selectively killing cancer cells, wherein the composition comprises a compound of Formula (I). The selective killing of cancer cells occurs with an improved potency and safety profile compared to similar compounds. In particular, the compositions and methods of the invention show reduced platelet toxicity and retained or improved toxicity in cancer cells.

The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.